Plain-English translation of NCT07516132 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a long-term safety study for patients who have already completed two years of treatment with (Axitinib Implant), a small implant placed inside the eye to help slow vision loss from wet age-related macular degeneration. The trial follows these patients to understand how safe and well-tolerated the medication remains over an even longer period. About 850 patients from previous studies who did well with the treatment are invited to continue.
Wet age-related macular degeneration is a serious eye condition that can cause vision loss, especially in older adults. While this medication has shown promise in earlier studies, doctors need to understand whether it remains safe and effective when patients use it for many years. This trial fills that gap by tracking patients long-term.
You likely qualify if…
You likely don't qualify if…
Since you will have already received the implant in an earlier study, this trial mainly involves regular follow-up visits to monitor how your eye is doing over time. You will continue with the same medication and have imaging and eye exams to check for any side effects and how well your vision is being preserved. The study continues the long-term care you started in the previous research.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States